Dogwood Therapeutics, Inc. (DWTX)
NASDAQ: DWTX · Real-Time Price · USD
3.280
+0.190 (6.15%)
At close: Jan 27, 2026, 4:00 PM EST
3.080
-0.200 (-6.10%)
After-hours: Jan 27, 2026, 4:18 PM EST
Dogwood Therapeutics Employees
Dogwood Therapeutics had 12 employees as of December 31, 2024. The number of employees increased by 8 or 200.00% compared to the previous year.
Employees
12
Change (1Y)
8
Growth (1Y)
200.00%
Revenue / Employee
n/a
Profits / Employee
-$3,331,297
Market Cap
105.23M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 12 | 8 | 200.00% |
| Dec 31, 2023 | 4 | 0 | - |
| Dec 31, 2022 | 4 | -1 | -20.00% |
| Dec 31, 2021 | 5 | 2 | 66.67% |
| Dec 31, 2020 | 3 | - | - |
| Sep 30, 2020 | 4 | - | - |
| Jun 30, 2020 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Agenus | 316 |
| Champions Oncology | 213 |
| Inovio Pharmaceuticals | 134 |
| Seer, Inc. | 134 |
| Korro Bio | 104 |
| MindWalk Holdings | 102 |
| Fortress Biotech | 101 |
| Pyxis Oncology | 44 |
DWTX News
- 15 days ago - Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development - GlobeNewsWire
- 5 weeks ago - Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain - GlobeNewsWire
- 2 months ago - Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045 - Accesswire
- 2 months ago - Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025 - Accesswire
- 2 months ago - Dogwood Therapeutics Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 - Accesswire
- 3 months ago - Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025 - Accesswire
- 4 months ago - Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit - Accesswire